BridgeBio Pharma (BBIO) Net Income towards Common Stockholders (2018 - 2026)

BridgeBio Pharma has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$164.0 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 2.02% year-over-year to -$164.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$721.6 million (down 8.02% YoY) and the FY2025 annual result came in at -$724.9 million, down 35.31% from the prior year.
• Net Income towards Common Stockholders advanced to -$164.0 million in Q1 2026 per BBIO's latest filing, from -$192.9 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$9.9 million in Q2 2022 and troughed at -$265.0 million in Q4 2024.
• A 5-year average of -$149.9 million and a median of -$164.0 million in 2026 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders soared 89.77% in 2022, then tumbled 1502.06% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at -$137.6 million in 2022, then dropped by 22.21% to -$168.1 million in 2023, then tumbled by 57.63% to -$265.0 million in 2024, then advanced by 27.24% to -$192.9 million in 2025, then grew by 14.94% to -$164.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$164.0 million, -$192.9 million, and -$182.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.